<DOC>
	<DOCNO>NCT01276990</DOCNO>
	<brief_summary>To investigate safety pharmacokinetic BI 224436 healthy male volunteer follow oral administration repeat dos 10 day within 8 dose regimen .</brief_summary>
	<brief_title>Safety Pharmacokinetics Multiple Rising Oral Doses BI 224436 Healthy Male Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male accord follow criterion : base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test . 2 . Age &gt; =18 &lt; =50 year . 3 . Body Mass Index ( BMI ) &gt; =18.5 BMI &lt; =32 kg/m2 . 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation . 5 . Documented sterile ; , father child , agree abstain sexual intercourse least seven day follow last study drug administration , willing use condom period time ( Subject 's female sexual partner ( ) childbearing potential willing use either ethinyl estradiol contain oral contraceptive reliable barrier method contraception ) . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance accord opinion investigator . 2 . Any evidence clinically relevant concomitant disease . 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder . 4 . Surgery gastrointestinal tract opinion investigator may affect absorption . 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder . 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . History evidence Human Immunodeficiency Virus chronic relevant acute infection , include Hepatitis C Virus Hepatitis B Virus infection . 8 . History relevant allergy / hypersensitivity ( include allergy investigational medicinal product solvent ) . 9 . History familial skeletal muscle disorder , history Creatine Kinase ( CK ) elevation due strenuous physical activity trauma . 10 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial . 11 . Use drug , include prescription nonprescription drug , St. Johns Wort might reasonably influence result trial within 14 day prior study drug administration trial , consumption grapefruit , grapefruit juice , orange juice , Seville oranges , green tea , pineapple , pineapple juice , broccoli red wine within 3 day prior study drug administration trial . 12 . Participation another trial investigational drug within one month prior administration trial . 13 . Current smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipe / day ) . 14 . Inability refrain smoke trial . 15 . Alcohol abuse ( 30 g day ) . 16 . Drug abuse . 17 . Blood donation ( 100 mL within four week prior administration trial ) . 18 . Physical activity excess usual activity daily living ( e.g. , fitness physical exercise , physical labor ) within 7 day prior study drug administration end study visit . 19 . Any laboratory value outside reference range opinion investigator clinical relevance . 20 . A marked baseline prolongation QT correct QT ( QTc ) interval ( e.g. , repeat demonstration QTc interval &gt; 450 m ) ; , ECG abnormality clinical significance . 21 . A history additional risk factor Torsades de point ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . 22 . CK screen =2x Upper Limit Normal ( ULN ) ( If CK =2xULN &lt; 5xULN one retest allow verify result ) . 23 . CK baseline ( Day 1 ) &gt; ULN ( If CK &gt; ULN &lt; 1.5xULN one retest allow verify result ) . 24 . Thyroid stimulate hormone outside normal reference range , history hypoor hyperthyroidism .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>